Renaissance Technologies’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-6,074
| Closed | -$334K | – | 4604 |
|
|
2022
Q2 | $334K | Sell |
6,074
-86,400
| -93% | -$4.53M | ﹤0.01% | 3395 |
|
|
2022
Q1 | $2.96M | Sell |
92,474
-18,561
| -17% | -$533K | ﹤0.01% | 1930 |
|
|
2021
Q4 | $2.41M | Buy |
111,035
+5,761
| +5% | +$127K | ﹤0.01% | 1993 |
|
|
2021
Q3 | $2.31M | Sell |
105,274
-900
| -0.8% | -$18K | ﹤0.01% | 1976 |
|
|
2021
Q2 | $2.07M | Sell |
106,174
-1,300
| -1% | -$23.6K | ﹤0.01% | 2239 |
|
|
2021
Q1 | $1.85M | Buy |
107,474
+700
| +0.7% | +$11.1K | ﹤0.01% | 2280 |
|
|
2020
Q4 | $1.71M | Buy |
106,774
+5,700
| +6% | +$79.2K | ﹤0.01% | 2215 |
|
|
2020
Q3 | $1.08M | Buy |
101,074
+6,600
| +7% | +$78.6K | ﹤0.01% | 2480 |
|
|
2020
Q2 | $1.14M | Buy |
94,474
+9,500
| +11% | +$118K | ﹤0.01% | 2476 |
|
|
2020
Q1 | $834K | Sell |
84,974
-1,438
| -2% | -$18.8K | ﹤0.01% | 2515 |
|
|
2019
Q4 | $1.18M | Buy |
86,412
+20,618
| +31% | +$269K | ﹤0.01% | 2552 |
|
|
2019
Q3 | $1.03M | Buy |
65,794
+7,978
| +14% | +$153K | ﹤0.01% | 2584 |
|
|
2019
Q2 | $1.29M | Buy |
57,816
+10,433
| +22% | +$505K | ﹤0.01% | 2569 |
|
|
2019
Q1 | $3.24M | Buy |
47,383
+2,163
| +5% | +$139K | ﹤0.01% | 2068 |
|
|
2018
Q4 | $2.39M | Sell |
45,220
-11,086
| -20% | -$708K | ﹤0.01% | 2133 |
|
|
2018
Q3 | $3.83M | Buy |
56,306
+12,133
| +27% | +$1.1M | ﹤0.01% | 1962 |
|
|
2018
Q2 | $5.23M | Sell |
44,173
-1,660
| -4% | -$167K | 0.01% | 1765 |
|
|
2018
Q1 | $3.79M | Buy |
45,833
+27,365
| +148% | +$3.1M | ﹤0.01% | 1997 |
|
|
2017
Q4 | $2.75M | Buy |
18,468
+10,358
| +128% | +$996K | ﹤0.01% | 2154 |
|
|
2017
Q3 | $503K | Buy |
8,110
+5,297
| +188% | +$311K | ﹤0.01% | 2784 |
|
|
2017
Q2 | $132K | Buy |
+2,813
| New | +$144K | ﹤0.01% | 3052 |
|
|
2016
Q4 | – | Sell |
-5,645
| Closed | -$411K | – | 3545 |
|
|
2016
Q3 | $411K | Buy |
+5,645
| New | +$436K | ﹤0.01% | 2864 |
|
|
2016
Q2 | – | Sell |
-1,133
| Closed | -$305K | – | 3570 |
|
|
2016
Q1 | $305K | Buy |
1,133
+158
| +16% | +$50.5K | ﹤0.01% | 2977 |
|
|
2015
Q4 | $587K | Buy |
+975
| New | +$660K | ﹤0.01% | 2683 |
|
Other funds holding SRRA
Renaissance Technologies's SRRA Position: Q3 2022 in Review
Renaissance Technologies sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 6,074 shares — an estimated $334K sold.
Renaissance Technologies first reported a position in SRRA in Q4 2015 and held it in 24 quarters. The position peaked at $5.23M in Q2 2018. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- Renaissance Technologies reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Renaissance Technologies sold 6,074 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $334K.
- Renaissance Technologies first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2015 and held it in 24 quarters.
- Renaissance Technologies's Sierra Oncology, Inc. Common Stock position peaked at $5.23M in Q2 2018.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on Renaissance Technologies's 13F filing for Q3 2022, filed 14 Nov 2022.